Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

https://www.thelancet.com/coronavirus?dgcid=hubspot_email_conferencealerts_lancetcams23&utm_campaign=conferencealerts&utm_medium=email&_hsmi=283611355&_hsenc=p2ANqtz-8L9ZFz0J7fZMdh3FB_gnZu-mphxLBiIuM0zrzzz5ekHFD-dYE1Lu58l1WX1nDsGNh-08W-2tp9Yzbf528mXFsh-dTkKA&utm_content=283611355&utm_source=hs_email